Genomic Vision : The Cologne Center for Genetics (CCG), a Major European Core Facility in Genetic Analysis, Adopts the Molecu...
July 12 2017 - 2:00AM
Business Wire
- After several months of testing, a new
center of excellence in genomic technologies adopts molecular
combing
- This technology will offer the teams of
Prof. Nürnberg the ability to accelerate the discovery of new
biomarkers for genetic diseases and the best care for undiagnosed
patients
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a company
specialized in the development of diagnostic solutions for the
early detection of cancers and serious genetic diseases and tools
for life sciences research today announced the adoption of its
molecular combing technology with the use of the FiberVision®
platform by the Cologne Center for Genomics (CCG) to further
develop the medical biology research and accelerate the discovery
of new biomarkers.
The CCG’s core facility, one of the major European centers for
genetic analysis renowned for adopting the most innovative medical
technologies, has tested for a few months the FiberVision®
platform. At the end of this period, the CCG has just confirmed the
implementation of molecular combing as the tool to improve its
research capacity in DNA structural variations in the hereditary
diseases and cancers or in the identification of complex genetic
disorders.
Thanks to a direct visualization of the long strands of DNA, the
molecular combing technology, on which the platform FiberVision® is
based, provides a useful addition to the existing sequencing
technologies in the search for new genetic biomarkers.
Prof. Dr. Peter Nürnberg, principal investigator of the Cologne
Center for Genomics, stated: “We are excited to have this
complementary new technology in our Core Facility. We have already
obtained promising results on the Complement Factor H for the early
diagnosis of Atypical Hemolytic Uremic Syndrome (aHUS), allowing to
find undetected genomic deletions in symptomatic patients. Its use
will be extended to more pathologies and to serve both our research
and clinical departments.”
David Del Bourgo, Director of Marketing & Sales of Genomic
Vision, concluded: “The adoption of our FiberVision® platform by a
leading player in genetic analysis, such as the CCG, is a real
recognition of our technology. The CCG and the teams of Prof.
Nürnberg are at the forefront in the use of new generation
sequencing technologies and have quickly integrated the
opportunities provided by molecular combing. By allowing an
analysis of the DNA structural variations without ambiguity, our
platform offers a real asset to the CCG teams in the fundamental
understanding of specific genetic pathologies and in the care of
their undiagnosed patients.”
ABOUT GENOMIC VISIONGENOMIC VISION is a company
specialized in the development of diagnostic solutions for the
early detection of cancers and serious genetic diseases and tools
for life sciences research. Through the DNA Molecular Combing, a
strong technology allowing to identify genetic abnormalities,
GENOMIC VISION stimulates the R&D productivity of the
pharmaceutical companies, the leaders of the diagnostic industry
and the research labs. The Company develops a robust portfolio of
diagnostic tests (breast, ovarian and colorectal cancers,
myopathies) and analysis tools (DNA replication, biomarkers
discovery, gene editing quality control). Based near Paris, in
Bagneux, the Company has approximately 60 employees. GENOMIC VISION
is a public listed company listed in compartment C of Euronext’s
regulated market in Paris (Euronext: GV - ISIN: FR0011799907). For
further information, please visit www.genomicvision.com
Member of CAC® Mid & Small and
CAC® All-Tradable indexes
FORWARD LOOKING STATEMENTThis press release contains
implicitly or explicitly certain forward-looking statements
concerning Genomic Vision and its business. Such forward-looking
statements are based on assumptions that Genomic Vision considers
to be reasonable. However, there can be no assurance that such
forward-looking statements will be verified, which statements are
subject to numerous risks, including the risks set forth in the
“Risk Factors” section in its Document de Reference filed with the
French Autorité des Marchés Financiers (AMF) on March 28, 2017,
under number R.17-009, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170711006658/en/
Genomic VisionAaron Bensimon, +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorMilestonesPress
RelationsBruno Arabian, +33 1 83 62 34
84barabian@milestones.frorNewCapInvestor RelationsDušan
Orešanský / Emmanuel Huynh, +33 1 44 71 94 92gv@newcap.eu
Goldfield (AMEX:GV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Goldfield (AMEX:GV)
Historical Stock Chart
From Apr 2023 to Apr 2024